|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0013203,
umls-concept:C0036667,
umls-concept:C0087111,
umls-concept:C0109317,
umls-concept:C0162638,
umls-concept:C0312418,
umls-concept:C0599894,
umls-concept:C0752312,
umls-concept:C0752313,
umls-concept:C1150579,
umls-concept:C1333340,
umls-concept:C1366882,
umls-concept:C1370600,
umls-concept:C1521840,
umls-concept:C1704259,
umls-concept:C1705767,
umls-concept:C1705791,
umls-concept:C1705987
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2010-5-31
|
|
pubmed:abstractText |
The effects of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways on proliferation, drug resistance, prevention of apoptosis and sensitivity to signal transduction inhibitors were examined in FL/DeltaAkt-1:ER*(Myr(+)) + DeltaRaf-1:AR cells which are conditionally-transformed to grow in response to Raf and Akt activation. Drug resistant cells were isolated from FL/DeltaAkt-1:ER*(Myr(+)) + DeltaRaf-1:AR cells in the presence of doxorubicin. Activation of Raf-1, in the drug resistant FL/DeltaAkt-1:ER*(Myr(+)) + DeltaRaf-1:AR cells, increased the IC(50) for doxorubicin 80-fold, whereas activation of Akt-1, by itself, had no effect on the doxorubicin IC50. However, Akt-1 activation enhanced cell proliferation and clonogenicity in the presence of chemotherapeutic drugs. Thus the Raf/MEK/ERK pathway had profound effects on the sensitivity to chemotherapeutic drugs, and Akt-1 activation was required for the long term growth of these cells as well as resistance to chemotherapeutic drugs. The effects of doxorubicin on the induction of apoptosis in the drug resistant cells were enhanced by addition of either mTOR and MEK inhibitors. These results indicate that targeting the Raf/MEK/ERK and PI3K/Akt/mTOR pathways may be an effective approach for therapeutic intervention in drug resistant cancers that have mutations activating these cascades.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1551-4005
|
|
pubmed:author |
pubmed-author:AbramsStephen LSL,
pubmed-author:BäseckeJörgJ,
pubmed-author:ChappellWilliam HWH,
pubmed-author:DoniaMarcoM,
pubmed-author:LibraMassimoM,
pubmed-author:MartelliAlberto MAM,
pubmed-author:McCubreyJames AJA,
pubmed-author:NicolettiFerdinandoF,
pubmed-author:SheltonJohn GJG,
pubmed-author:SteelmanLinda SLS,
pubmed-author:StivalaFrancaF,
pubmed-author:WongEllis W TEW
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
9
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1781-91
|
|
pubmed:meshHeading |
pubmed-meshheading:20436278-Antineoplastic Agents,
pubmed-meshheading:20436278-Apoptosis,
pubmed-meshheading:20436278-Cell Line, Tumor,
pubmed-meshheading:20436278-Cell Proliferation,
pubmed-meshheading:20436278-Doxorubicin,
pubmed-meshheading:20436278-Drug Resistance, Neoplasm,
pubmed-meshheading:20436278-Extracellular Signal-Regulated MAP Kinases,
pubmed-meshheading:20436278-Humans,
pubmed-meshheading:20436278-Leukemia, Promyelocytic, Acute,
pubmed-meshheading:20436278-MAP Kinase Signaling System,
pubmed-meshheading:20436278-Mitogen-Activated Protein Kinase Kinases,
pubmed-meshheading:20436278-Protein Kinase Inhibitors,
pubmed-meshheading:20436278-Proto-Oncogene Proteins c-akt,
pubmed-meshheading:20436278-raf Kinases
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy.
|
|
pubmed:affiliation |
Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University, Greenville, NC, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
